Harvoni, noul tratament contra hepatitei C cu rata de vindecare 94 - 99% pentru $1,125/pastila

Gilead’s latest hepatitis C drug breaks US sales records

Quote

http://www.ft.com/cm...l#axzz3HTRQSG7P

Bravo lor, nu au rivali ! De aia si vand la pretul ala !

Edited by chaosss, 28 October 2014 - 22:59.

Prietenul meu in Canada a facut tratamentul gratis pt ca era experimental.S-a vindecat dar un a fost usor.Si parul din cap a inceput sa-si cada in timpul tratamentului.Pe bani il costa 60 mii dolari.

[ http://ei.marketwatch.com//Multimedia/2015/01/05/Photos/ZH/MW-DC588_solvad_20150105125332_ZH.jpg?uuid=ce46bb10-9503-11e4-b54a-837b1e5be82c - Pentru incarcare in pagina (embed) Click aici ]
http://www.marketwat...?dist=countdown

LOS ANGELES (MarketWatch) — Shares of Gilead Sciences Inc. were up more than 2% Monday after the biotechnology giant scored an exclusive rights deal with the nation’s largest drug-store chain, CVS Health Corp., for two Hepatitis C treatments that cost $1,000 per pill or more.
Starting Wednesday, Gilead’s GILD, +2.39%  Harvoni and Sovaldi — both considered highly effective treatments for Hepatitis C — will be offered exclusively via CVS’s CVS, -0.85%  standard commercial plans, health exchange marketplaces, Medicare Part D and Medicaid formularies.
Although Gilead has been heavily criticized in some health-care circles for the high prices imposed on these drugs, CVS officials say they currently are the best option for patients.
“Our goal was to create the lowest net-cost solution for the entire population of patients with all genotypes of Hepatitis C,” CVS spokeswoman Christine Cramer said in an e-mailed statement. “When making this decision, we evaluated a wide variety of factors including duration of therapy, relative distribution of genotype and cost of the individual agents in the category as well as the results of a comprehensive clinical review of the different Hepatitis C regimens.”
Put on the market in late 2013, Sovaldi has drawn the wrath of health insurers for its heavy price tag of $84,000 over 12 weeks, or $1,000 a pill. Gilead followed that up last October with Harvoni. Harvoni costs about $1,125 per pill, but the regimen can be completed in eight weeks for some patients, or $63,000.
The announcement is a setback for AbbVie Inc. ABBV, -1.82%  , whose rival drug to Harvoni and Sovaldi -- known as Viekira Pak -- received FDA approval just last month. Shares of AbbVie were down 3% to $63.94 in recent action. Gilead climbed 2.3% to $97.05.
CVS said Viekira Pak will only be available in cases of a medical exception or prior authorization. Pharmacy benefit manager Express Scripts Holding Co. ESRX, -0.52%  last month gave preferred formulary status to AbbVie’s drug, and caused Gilead’s shares to fall on concerns that Viekira Pak would prove to be a cheaper alternative to Sovaldi and Harvoni.
But Viekira Pak’s list price now stands at $83,320 for a 12-week regimen, not that much of a discount to either of the Gilead drugs. It’s possible, though, that AbbVie’s drug will be sold at lower prices behind the scenes, reports say.
Either way, it puts the skids on further discounting of Gilead shares, which have tumbled from around $108 a share since AbbVie won the FDA OK and scored the Express Scripts deal, says Micheal Yee, analyst with RBC Capital Markets.
“We view this as positive because it removes near-term uncertainty for many investors who feared CVS would also strike a deal with [AbbVie] and further put more pressure on [Gilead],” Yee said in a note to clients. He sees Gilead shares climbing higher since Hepatitis C drug sales are in line with estimates and that AbbVie’s deal with Express Scripts caused Gilead investors to pull back more than was warranted.
Further, CVS officials said in a release issued last month that they see Harvoni augmenting rather than replacing Sovaldi sales.
“Uptake for Harvoni is approximately 2.5 times the rate of Sovaldi prescribing during the weeks following Sovaldi’s launch in December 2013,” CVS said in a press release dated Dec. 18, the day before it was announced Viekira Pak received FDA approval. “In addition, the data shows there has been minimal reduction in Sovaldi use following the launch of Harvoni, suggesting an expansion in the pool of patients being treated, rather than Harvoni being used as a substitute for Sovaldi.”

Edited by lex404, 05 January 2015 - 22:38.
posteaza si continutul articolului

Numai in romania nu se face nimic in privinta asta
A mai iesit si viekira pak de la abbvie la un pret de 83000$

http://www.hepatitis...oved-for-hep-c/

Guvernele din franta ,germania etc etc au incheiat deal-uri cu gilead si il cumpara mai ieftin
Asa ar putea face si guvernul romaniei daca ar fi guvern


Astia in romania vorbesc despre introducerea triplei terapii care este deja depasita din 2013 de cand a iesit sovaldi pe piata

Stiu ca la un moment dat Gilead era in discutii cu India si Egipt pentru a produce Sovaldi la un pret de 900 de dolari pentru tot tratamentul necesar pentru 3 luni.

Medicamentul ar fi urmat sa fie produs direct in tarile respective, Egipt fiind tara cu cei mai multi bolnavi de hepatita C din lume.

chaosss, on 05 ianuarie 2015 - 22:41, said:

Stii foarte bine ce stii dar nu te poti duce sa-l cumperi la liber de acolo ( din ce stiu eu )
Dar daca afli ceva da de veste

Nu stiu daca era pentru producerea medicamentelor ci de vanzarea lor catre guvernele respectivelor tari
Cred ca in egipt au intrat deja

Gilead nici macar nu au un office in romania
Abbvie parca am gasit ceva pe net

zippo68, on 28 octombrie 2014 - 22:52, said:

Cu harvoni sau sovaldi si olisyo ?

Da, corect.


Gilead Offers Egypt 99% Price Cut for Sovaldi

Quote

http://www.hepmag.co...831_25391.shtml

Din pacate, pana sa ajunga Harvoni accesibil la noi va dura...
Aceasi poveste si cu alte tratamente importante...

Aha ,acum vad ca e posibil sa de licienta pt fabricare in india

lex404, on 05 ianuarie 2015 - 22:50, said:

Accesibil ca accesibil dar handicapatii astia nu-l au nici macar disponibil ca nu a fost aprobat de comisia de medicamente and cacat
Chiar azi am sunat la minister la cnas si inca in vreo 3 locuri ca sa intreb
Interes zero

Daca ar negocia cu companiile producatoare l-ar scoate la un maxim de 20.000€
Dar dupa cum am zis ,interes zero, bataia de joc continua cu succes

Si Sovaldi a fost aprobat doar la nivel centralizat de EMA si este oficial la un pret de 73934.1 RON/ 28 comprimate filmate.
Still waiting for Harvoni... nu e nimic publicat la 1 Ian.

Ce inseamna EMA ?

chaosss, on 05 ianuarie 2015 - 23:00, said:

European Medicines Agency

lex404, on 05 ianuarie 2015 - 22:57, said:

Iese mai scump ca la americani
Franta a negociat la 14000€ pe cutie ,daca tin eu bine minte

petre69, on 05 ianuarie 2015 - 23:01, said:

am sa ma interesez si la francezi, chiar sunt curios...

lex404, on 05 ianuarie 2015 - 23:01, said:

Eu daca as vrea sa il cumpar cu pretul ala mare ce ar trebui sa fac ?

chaosss, on 05 ianuarie 2015 - 23:07, said:

Sunt protocoale terapeutice prin CNAS  ( dar care nu pomenesc nimic de el ). Se face reteta, se comanda, se administreaza.
Bineinteles, in Romania sistemul merge prost.


ps. sovaldi e abia pe locul 5 ca pret...

Edited by lex404, 05 January 2015 - 23:24.